Gene
FLT1
FLT1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (126), Actionable biomarkers (1), Trial mentions (185), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FLT1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 20 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 4 of 8,738 | 0.05% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 5 of 8,597 | 0.06% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 38 of 11,460 | 0.33% |
| 2022 | 5 of 8,285 | 0.06% | 55 of 13,598 | 0.40% |
| 2021 | 11 of 8,692 | 0.13% | 68 of 15,045 | 0.45% |
| 2020 | 5 of 7,640 | 0.07% | 45 of 14,459 | 0.31% |
| 2019 | 8 of 7,300 | 0.11% | 54 of 12,159 | 0.44% |
| 2018 | 10 of 6,927 | 0.14% | 57 of 11,854 | 0.48% |
| 2017 | 9 of 6,558 | 0.14% | 45 of 11,595 | 0.39% |
Showing 10 of 37 years.
Assay-provider ledger (126)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 48 | September 03, 2026 +3 undated |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 11 | September 03, 2026 |
| Meso Scale Diagnostics | Reagent supplier | Clinical validationAnalytical validation | 2 | September 01, 2026 |
| SOMALogic, Inc | Reagent supplier | Clinical validationAnalytical validation | 1 | September 01, 2026 |
| ROCHE | Context dependent | Clinical validationAnalytical validation | 12 | August 01, 2026 +1 undated |
Showing 5 of 126 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FLT1 overexpression | SUNITINIB | response-associated | renal carcinoma | Cancer Genome Interpreter |
Trial mentions (185)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06383858 | Trial biospecimen (AACT) |
| NCT03204838 | Trial biospecimen (AACT) |
| NCT01921998 | Trial biospecimen (AACT) |
| NCT01679743 | Trial eligibility (AACT) |
| NCT03541889 | Trial eligibility (AACT) |
Showing 5 of 185 trial mentions.
Target-disease associations (464)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of refraction | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Abruptio Placentae | pregnancy or perinatal disease | Literature (Europe PMC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 464 associations.
Vendor sourcing (481)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AVEO Oncology (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | VEGFR1 | View trial NCT01782313 |
| Adil Daud | Trial sponsor | Mentioned in trial textTrial free-text mention | FLT | View trial NCT01174238 |
| Akinion Pharmaceuticals AB | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Patients who are candidates for induction chemotherapy for AML * Total WBC count ≥ 60,000/mm3; * Evidence of active central nervous system (CNS) leukemi... | View trial NCT01573247 |
| Akinion Pharmaceuticals AB | Trial sponsor | Mentioned in trial textTrial free-text mention | FLT | View trial NCT01573247 |
| Alexion Pharmaceuticals (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | Fms-like tyrosine kinase 1 | View trial NCT04725812 |
Showing 5 of 481 sourcing records.
Trial-cited literature (905)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated Vasculitis. | Journal of the American Society of Nephrology : JASN | 2026 | 5 |
| sFlt-1/PlGF Ratio Predicts Short-Term Maternal-Fetal Outcomes in Chinese Hypertensive Pregnancies: A Prospective Cohort Study. | Hypertension (Dallas, Tex. : 1979) | 2026 | 1 |
| Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial. | Communications medicine | 2025 | 27 |
| Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial. | Nature medicine | 2025 | 16 |
| Antiferroptotic Drugs Reduce sFlt-1 Release and Placenta Damage in Preeclampsia. | Hypertension (Dallas, Tex. : 1979) | 2025 | 8 |
Showing 5 of 905 papers.
Protein variant mentions (3)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.E298D | 1 | 2011 | PMID 21429808 |
| p.K15050D | 1 | 2016 | PMID 26970832 |
| p.S1031C | 1 | 2014 | PMID 25260786 |
Literature-extracted relations (207)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Anhydrous glucose | Chemical | associate |
Study protocol for a Developmental Epidemiological Study of Children born through Reproductive Technologies (DESCRT). | 2023 |
| lipids | Chemical | associate |
Study protocol for a Developmental Epidemiological Study of Children born through Reproductive Technologies (DESCRT). | 2023 |
| Cabergoline | Chemical | negative_correlate |
Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate. | 2021 |
| AXITINIB | Chemical | negative_correlate |
Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. | 2021 |
| Aspirin | Chemical | negative_correlate |
Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine kinase 1 production: a putative mechanism for preventing preeclampsia. | 2019 |
Showing 5 of 207 relation assertions.
Organizations publishing (553)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 39 | 2006 to 2023 |
| Harvard Medical School | Academic | 37 | 2004 to 2025 |
| Mass General Brigham | Hospital | 24 | 2004 to 2025 |
| The University of Texas System | Academic | 21 | 1995 to 2025 |
| Beth Israel Deaconess Medical Center | Hospital | 20 | 2002 to 2023 |
Showing 5 of 553 organizations.
Where FLT1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
389 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.